Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis

Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis

Bibliographic Details
Main Authors: A.S. Bjartell, D. Ye, N. Agarwal, B.H. Chung, R. Given, A. Merseburger, M. Özgüroğlu, A. Juárez Soto, H. Uemura, A. Lopez-Gitlitz, G. Li, S. Mc Carthy, K.N. Chi, S. Chowdhury
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:European Urology Open Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168320331591
Description
ISSN:2666-1683

Similar Items